CION Ameerpet
Common Questions · Reviewed by CION Oncologists · NABH Accredited
Life Expectancy — How to Read the Statistics
You came here for a number, and this page will not give you one — not out of evasion, but because the number you would find is not the thing you are looking for. Every survival figure published anywhere describes a group of women diagnosed years ago, averaged across every age, every stage, every general health state and every treatment. It tells you what happened to them. It cannot tell you what will happen to you. What this page does instead is teach you to read those figures properly, because you will encounter them, and understanding them is what stops them doing damage.
- Every figure is historical — by construction, not by neglect
- “Five-year survival” is misread constantly — it does not mean five years
- Averages describe groups — and you are not an average
- Your stage matters more than the headline — ask about that instead
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What the Terms Actually Mean
Five terms you will encounter, and what each does and does not say.
| Term | What it actually means |
|---|---|
| Five-year survival | The proportion of a group alive five years after diagnosis. A measuring point, not a life expectancy. Most women counted as alive at five years go on to live decades — and for early endometrial cancer, many are simply cured. |
| Relative survival | Compares survival in the cancer group with what would be expected in similar people without cancer, adjusting for deaths from other causes. Usually higher than the raw figure, particularly in older groups. It is a population measure, not your personal odds. |
| Median survival | The midpoint of a wide spread — half the group did better, some by a very long way. Reading a median as an expected lifespan is a serious misreading, and it is the number that causes the most unnecessary distress. |
| Stage-specific survival | Considerably more useful than any overall figure, because overall figures average situations that have almost nothing in common. Ask about your stage. See survival by stage. |
| Overall survival for “endometrial cancer” | The least useful number available, and the one that appears first in search results. It averages a woman with grade 1 disease confined to the lining and a woman with widespread disease, which describes neither. |
Every published figure is historical by construction. A five-year figure needs five years of follow-up, plus time for collection, analysis and publication. So it describes treatment given years ago — before molecular classification entered staging, and before several current systemic treatments existed. The lag is not neglect; it is arithmetic.
Did You Know? The most misread statistic in oncology is “five-year survival”. It does not mean people survive for five years. It is simply a measuring point — the proportion of a group still alive when someone counted at the five-year mark — chosen because it is long enough to be meaningful and short enough to be practical. Most women counted as surviving at five years go on to live decades. For endometrial cancer specifically, most cases are diagnosed early and many women are cured by surgery alone. Reading a five-year figure as a life expectancy is one of the commonest and most distressing errors people make with these numbers. Sources: SEER Cancer Statistics Review, National Cancer Institute; National Cancer Registry Programme, Indian Council of Medical Research; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Why the Number Does Not Describe You
Five specific reasons, beyond the general point about averages.
- They average across all stages. Unless you have found a stage-specific figure, you are reading a blend of early curable disease and advanced disease. Your situation is one of those, not the average of both.
- They average across all ages and health states. Including women who were frail, who had other serious illnesses, or who could not have the full treatment. If you are fit and had complete surgery, the average is not a description of you.
- They predate molecular classification. Which is now part of FIGO 2023 staging, can move treatment in either direction, and did not exist when the data were collected. See molecular classification.
- They predate current systemic treatment. Options in advanced and recurrent endometrial cancer have changed substantially in recent years, particularly for mismatch repair deficient tumours. Older data cannot reflect that.
- Indian data is limited. Most published figures come from registries in the United States and Europe. That is a genuine limitation of the evidence rather than a reason to assume a worse outcome.
Want Your Own Situation Explained?
Your stage, your grade, your molecular class — rather than a figure that describes a population.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Five-Year Survival Does Not Mean Five Years
It is a measuring point. Most women counted as surviving go on to live decades.
Better Questions to Ask
These have real answers, in a way that “how long have I got” does not.
"What is my stage, and what does that mean for me?"
Stage is the strongest determinant of outcome, and stage-specific information is genuinely more useful than any headline figure. Most endometrial cancers are found confined to the uterus, where outcomes are good, so this question frequently produces a more reassuring answer than the internet did.
"Is my treatment being given with the intention of curing me?"
A direct question with a direct answer, and one people are often afraid to ask. For most women with endometrial cancer the answer is yes — including many with node-positive disease. Hearing it said plainly matters more than any statistic.
"What is my molecular class, and did it change the plan?"
It is part of current staging and it refines prognosis in both directions — a POLE-ultramutated tumour behaves considerably better than its grade suggests. If it has not been done, ask whether it can be done on the stored tissue. See what affects prognosis.
"What happens next, and what would change the plan?"
Concrete, answerable, and far more useful for actually living than a probability. Knowing the sequence and the decision points converts an open-ended fear into a process you can follow.
"What should I watch for between appointments?"
Practical and empowering. Most recurrences are found because a woman reported a symptom, not through routine scans. See detecting recurrence.
Want a Straight Answer About Your Own Case?
Bring your reports. Your stage and what it means, explained properly. The opinion is free.
If You Are Going to Search Anyway
Most people do, so here is how to do it with least harm.
- Search for your stage, not the disease. “Stage 1 endometrial cancer” returns something meaningfully different from “endometrial cancer survival”, and the first is a description of a situation closer to yours.
- Check the date on anything you read. Material from before molecular classification entered practice describes a different standard of care. Older pages rank well and age badly.
- Do not search at night. A practical rather than a patronising suggestion. Everything reads worse at two in the morning, and there is nobody to ask until daylight.
- Avoid forums for statistics. They are valuable for practical advice and for not feeling alone, and they systematically over-represent difficult outcomes, because women who recovered and got on with their lives stop posting.
- Write the question down and take it to your appointment. The single most useful habit. Questions carried in the head at midnight get worse; questions written down get answered. See coping with a diagnosis.
Why This Needs a Person, Not a Page
A statistic can only describe a population. What you actually want to know requires someone holding your report.
45-minute consultations
Tumour board for every diagnosis
MMR / MSI testing as standard
Costs explained before you commit
Psycho-oncology and nutrition on the team
Second opinions welcomed, not resented
Take The Next Step
Ask About Your Stage
It is the question with a real answer — and for most women it is a more reassuring one than the internet gave.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Understanding the Statistics — Frequently Asked Questions
What does five-year survival actually mean?
It is the proportion of a defined group of people who are alive five years after diagnosis — a measuring point chosen because it is long enough to be meaningful and short enough to be practical. It does not mean that people survive for five years, which is the commonest and most distressing misreading of these figures. Most women counted as surviving at five years go on to live decades, and for endometrial cancer specifically, most cases are diagnosed early and many women are cured by surgery alone. The figure describes a historical group, not a lifespan.
Why will nobody give me a number for my own case?
Because the honest answer is that no reliable individual number exists. Published statistics average across every stage, age, general health state and treatment, and they describe women diagnosed years ago — before molecular classification became part of staging and before several current treatments existed. Beyond that, the strongest predictor in an individual case is how the disease responds to treatment, which is not knowable in advance. What your oncologist can tell you is what your treatment is intended to achieve, whether it is being given with curative intent, and what would prompt a change of plan.
Are the statistics I find online out of date?
Necessarily, and by construction rather than through neglect. A five-year survival figure requires five years of follow-up after diagnosis, plus further time for data collection, analysis and publication — so any such figure describes treatment delivered years ago. For endometrial cancer that gap matters: molecular classification is now part of FIGO 2023 staging and can move treatment recommendations in either direction, and systemic treatment for advanced disease has changed substantially, particularly for mismatch repair deficient tumours. Also check the date on the page itself, since older material ranks well and ages badly.
Why is stage-specific information better?
Because an overall figure for "endometrial cancer" averages situations that have almost nothing in common — a woman with grade 1 disease confined to the lining of the uterus, and a woman with widespread disease, counted together. The resulting number describes neither. Stage-specific figures are considerably more informative, and figures that also account for histological type and molecular class more informative still. For most women this matters in a reassuring direction, because the majority of endometrial cancers are found while confined to the uterus, where outcomes are good.
What should I ask instead?
Ask what your stage is and what it means for you. Ask directly whether your treatment is being given with the intention of curing you — for most women with endometrial cancer, including many with involved lymph nodes, the answer is yes, and hearing it plainly is worth more than any figure. Ask what your molecular class is and whether it changed the plan. Ask what happens next and what would prompt a change. And ask what you should watch for between appointments, since most recurrences are found because a woman reported a symptom.
Medical disclaimer: This page explains how to interpret survival statistics in endometrial cancer and is reviewed by a CION oncologist. It deliberately does not publish survival figures, because published statistics describe groups of patients treated in the past and cannot predict outcome for any individual. Your own situation should be discussed with your treating team in the context of your complete pathology and clinical circumstances.